Table 2.
Hazard ratios and 95% confidence intervals for acute kidney injury associated with apixaban, rivaroxaban, dabigatran, and warfarin from network meta-analysis.
| Apixaban | Rivaroxaban | Dabigatran | Warfarin | |
|---|---|---|---|---|
| Overalla | ||||
| Compared to apixaban | 1 | 0.98 (0.85, 1.12) | 0.82 (0.68, 0.99) | 1.22 (1.10, 1.35) |
| Compared to rivaroxaban | 1.02 (0.89, 1.17) | 1 | 0.84 (0.72, 0.98) | 1.23 (1.16, 1.32) |
| Compared to dabigatran | 1.22 (1.01, 1.46) | 1.19 (1.02, 1.39) | 1 | 1.47 (1.30, 1.69) |
| Compared to warfarin | 0.82 (0.74, 0.91) | 0.81 (0.76, 0.86) | 0.68 (0.59, 0.77) | 1 |
| Patients without CKDb, c | ||||
| Compared to apixaban | 1 | 1.12 (0.83, 1.50) | 0.93 (0.69, 1.24) | 1.43 (1.05, 1.96) |
| Compared to rivaroxaban | 0.89 (0.67, 1.20) | 1 | 0.82 (0.63, 1.08) | 1.28 (1.06, 1.56) |
| Compared to dabigatran | 1.08 (0.81, 1.46) | 1.21 (0.92, 1.59) | 1 | 1.59 (1.49, 1.72) |
| Compared to warfarin | 0.70 (0.51, 0.95) | 0.78 (0.64, 0.94) | 0.63 (0.58, 0.67) | 1 |
| Patients with CKD | ||||
| Compared to apixaban | 1 | 1.02 (0.65, 1.57) | 0.80 (0.50, 1.24) | 1.54 (1.02, 2.33) |
| Compared to rivaroxaban | 0.98 (0.64, 1.53) | 1 | 0.78 (0.51, 1.19) | 1.45 (1.14, 1.85) |
| Compared to dabigatran | 1.25 (0.81, 1.99) | 1.28 (0.84, 1.95) | 1 | 1.89 (1.75, 2.04) |
| Compared to warfarin | 0.65 (0.43, 0.98) | 0.69 (0.54, 0.88) | 0.53 (0.49, 0.57) | 1 |
a
Studies included: Harel et al., 2021, Perez et al., 2021, Hernandez et al., 2020, Coleman et al., 2019, Shin et al., 2018, Yao et al., 2017.
b
Studies included: Harel et al., 2021, Hernandez et al., 2020, Chan et al., 2018, Shin et al., 2018, Yao et al., 2017, Chan et al., 2016.
c
CKD, chronic kidney disease, defined as either a documented history of chronic kidney disease or estimated glomerular filtration rate of 60 ml/min/1.73m2 or less.